Accelerated Delivery of Innovative Medicine

The Challenge

The emergence of precision medicine is making prolonged clinical response a realistic goal of lung cancer therapy; but to further improve lung cancer survival outcomes, we must explore the potential for precision medicines in earlier stages (Stage I-III) where there is a greater chance of cure.13,14

Our solution

Moving Earlier

As part of its Major Pathologic Response Project, the Alliance is validating surrogate endpoints to accelerate drug approval in early settings.  We are using our understanding of the molecular features of cancer to identify patients at high-risk of early relapse and who may benefit most from therapeutic intervention.15


  1. World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at Accessed August 2019
  2. EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
  3. Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at Accessed May 2019
  4. Yousaf-Khan U, et al. Final Screening Round of the NELSON Lung Cancer Screening Trial: The Effect of a 2.5-year Screening Interval. Thorax. 2017;72:48–56.
  5. The National Lung Screening Trial Research Team. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409.
  6. Midthun D. Early detection of lung cancer. F1000Research. 2016;5(F1000 Faculty Rev):739
  7. NICE. The diagnosis and treatment of lung cancer (update). Available at Accessed August 2019
  8. Mathur S, et al. Personalised medicine could transform health care. Biomed Rep. 2017; (1) 3-5
  9. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  10. Jemal a & Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281
  11. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at Accessed August 2019
  12. Giroux, DJ et al. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology. 2018;13(6):801-809
  13. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  14. Mascaux C, et al. Personalised medicine for nonsmall cell lung cancer. European Respiratory Review. 2017;26
  15. IASLC Pathology Committee. Available at Accessed August 2019